117TH CONGRESS 1ST SESSION

H. R. 4065

To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

June 22, 2021

Ms. Sewell (for herself and Mr. Buchanan) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
- 4 (a) Short Title.—This Act may be cited as the
- 5 "Chronic Kidney Disease Improvement in Research and
- 6 Treatment Act of 2021".
- 7 (b) Table of Contents.—The table of contents for
- 8 this Act is as follows:
 - Sec. 1. Short title; table of contents.

TITLE I—INCREASING AWARENESS, EXPANDING PREVENTIVE SERVICES. AND IMPROVING CARE COORDINATION

- Sec. 101. Expanding Medicare annual wellness benefit to include kidney disease screening.
- Sec. 102. Increasing access to Medicare kidney disease education benefit.
- Sec. 103. Improving patient lives and quality of care through research and innovation.
- Sec. 104. Understanding the progression of kidney disease and treatment of kidney failure in minority populations.

TITLE II—CREATING AN ECONOMICALLY STABLE DIALYSIS INFRASTRUCTURE AND INCENTIVIZING INNOVATION

Sec. 201. Refining the end-stage renal disease payment system to improve accuracy in payment and support therapies.

TITLE III—INCREASING PATIENT ACCESS TO QUALITY PERFORMANCE BY IMPROVING THE ACCURACY AND TRANSPARENCY OF END-STAGE RENAL DISEASE QUALITY PROGRAMS

Sec. 301. Improving patient decision making and transparency by consolidating and modernizing quality programs.

TITLE IV—EMPOWERING PATIENTS

- Sec. 401. Medigap coverage for beneficiaries with end-stage renal disease.
- Sec. 402. Network adequacy requirements for dialysis services.
- Sec. 403. Allowing individuals with kidney failure to retain access to private in-

TITLE I—INCREASING AWARE-

- 2 NESS, EXPANDING PREVEN-
- 3 TIVE SERVICES, AND IMPROV-
- 4 ING CARE COORDINATION
- 5 SEC. 101. EXPANDING MEDICARE ANNUAL WELLNESS BEN-
- 6 EFIT TO INCLUDE KIDNEY DISEASE SCREEN-
- 7 ING.
- 8 (a) IN GENERAL.—Section 1861(ww)(2) of the Social
- 9 Security Act (42 U.S.C. 1395x(ww)(2)) is amended—
- 10 (1) by redesignating subparagraph (O) as sub-
- 11 paragraph (P); and

1	(2) by inserting after subparagraph (N) the fol-
2	lowing new subparagraph:
3	"(O) Chronic kidney disease screening as
4	defined by the Secretary.".
5	(b) Effective Date.—The amendments made by
6	this section apply to items and services furnished on or
7	after January 1, 2022.
8	SEC. 102. INCREASING ACCESS TO MEDICARE KIDNEY DIS-
9	EASE EDUCATION BENEFIT.
10	(a) In General.—Section 1861(ggg) of the Social
11	Security Act (42 U.S.C. 1395x(ggg)) is amended—
12	(1) in paragraph (1)—
13	(A) in subparagraph (A), by inserting "or
14	stage V" after "stage IV"; and
15	(B) in subparagraph (B), by inserting "or
16	of a physician assistant, nurse practitioner, or
17	clinical nurse specialist (as defined in section
18	1861(aa)(5)) assisting in the treatment of the
19	individual's kidney condition" after "kidney
20	condition"; and
21	(2) in paragraph (2)—
22	(A) by striking subparagraph (B); and
23	(B) in subparagraph (A)—
24	(i) by striking "(A)" after "(2)";

1	(ii) by striking "and" at the end of
2	clause (i);
3	(iii) by striking the period at the end
4	of clause (ii) and inserting "; and";
5	(iv) by redesignating clauses (i) and
6	(ii) as subparagraphs (A) and (B), respec-
7	tively; and
8	(v) by adding at the end the following:
9	"(C) a renal dialysis facility subject to the
10	requirements of section 1881(b)(1) with per-
11	sonnel who—
12	"(i) provide the services described in
13	paragraph (1); and
14	"(ii) is a physician (as defined in sub-
15	section $(r)(1)$ or a physician assistant,
16	nurse practitioner, or clinical nurse spe-
17	cialist (as defined in subsection (aa)(5)).".
18	(b) Payment to Renal Dialysis Facilities.—
19	Section 1881(b) of the Social Security Act (42 U.S.C.
20	1395rr(b)) is amended by adding at the end the following
21	new paragraph:
22	"(15) For purposes of paragraph (14), the sin-
23	gle payment for renal dialysis services under such
24	paragraph shall not take into account the amount of
25	payment for kidney disease education services (as

- defined in section 1861(ggg)). Instead, payment for such services shall be made to the renal dialysis facility on an assignment-related basis under section 1848.".

 (c) Effective Date.—The amendments made by this section apply to kidney disease education services fur-
- 8 SEC. 103. IMPROVING PATIENT LIVES AND QUALITY OF

nished on or after January 1, 2022.

- 9 CARE THROUGH RESEARCH AND INNOVA-
- 10 **TION.**
- 11 (a) STUDY.—The Secretary of Health and Human
- 12 Services (in this section referred to as the "Secretary")
- 13 shall conduct a study on increasing kidney transplantation
- 14 rates. Such study shall include an analysis of each of the
- 15 following:
- 16 (1) Any disincentives in the payment systems 17 under the Medicare program under title XVIII of 18 the Social Security Act that create barriers to kid-
- 19 ney transplants and post-transplant care for bene-
- ficiaries with end-stage renal disease.
- 21 (2) The practices used by States with higher
- than average donation rates and whether those prac-
- tices and policies could be successfully utilized in
- other States.

1	(3) Practices and policies that could increase
2	deceased donation rates of minority populations.
3	(4) Whether cultural and policy barriers exist to
4	increasing living donation rates, including an exam-
5	ination of how to better facilitate chained donations.
6	(5) Other areas determined appropriate by the
7	Secretary.
8	(b) Report.—Not later than 18 months after the
9	date of the enactment of this Act, the Secretary shall sub-
10	mit to Congress a report on the study conducted under
11	subsection (a), together with such recommendations as the
12	Secretary determines to be appropriate.
12	SEC. 104. UNDERSTANDING THE PROGRESSION OF KIDNEY
13	SEC. 104. UNDERSTANDING THE PROGRESSION OF RIDNET
13	DISEASE AND TREATMENT OF KIDNEY FAIL-
14	DISEASE AND TREATMENT OF KIDNEY FAIL-
14 15	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS.
14 15 16 17	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human
14 15 16 17	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human Services (in this section referred to as the "Secretary")
14 15 16 17 18	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall conduct a study on—
14 15 16 17 18	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall conduct a study on— (1) the social, behavioral, and biological factors
14 15 16 17 18 19 20	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall conduct a study on— (1) the social, behavioral, and biological factors leading to kidney disease;
14 15 16 17 18 19 20 21	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) STUDY.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall conduct a study on— (1) the social, behavioral, and biological factors leading to kidney disease; (2) efforts to slow the progression of kidney dis-
14 15 16 17 18 19 20 21	DISEASE AND TREATMENT OF KIDNEY FAIL- URE IN MINORITY POPULATIONS. (a) Study.—The Secretary of Health and Human Services (in this section referred to as the "Secretary") shall conduct a study on— (1) the social, behavioral, and biological factors leading to kidney disease; (2) efforts to slow the progression of kidney disease in minority populations that are disproportion-

1	XVIII of the Social Security Act, the Medicaid pro-
2	gram under title XIX of such Act, and through pri-
3	vate health insurance, to minority populations that
4	are disproportionately affected by kidney failure.
5	(b) Report.—Not later than 1 year after the date
6	of the enactment of this Act, the Secretary shall submit
7	to Congress a report on the study conducted under sub-
8	section (a), together with such recommendations as the
9	Secretary determines to be appropriate.
10	TITLE II—CREATING AN ECO-
11	NOMICALLY STABLE DIALY-
12	SIS INFRASTRUCTURE AND
13	INCENTIVIZING INNOVATION
14	SEC. 201. REFINING THE END-STAGE RENAL DISEASE PAY-
15	MENT SYSTEM TO IMPROVE ACCURACY IN
16	PAYMENT AND SUPPORT THERAPIES.
17	(a) In General.—Section 1881(b)(14) of the Social
18	Security Act (42 U.S.C. 1395rr(b)(14)) is amended—
19	(1) in subparagraph (D), in the matter pre-
20	ceding clause (i), by striking "Such system" and in-
21	serting "Subject to subparagraph (J), such system";
22	and
23	(2) by adding at the end the following new sub-
	•

1	"(J) For payment for renal dialysis serv-
2	ices furnished on or after January 1, 2024,
3	under the system under this paragraph—
4	"(i) the payment adjustment de-
5	scribed in clause (i) of subparagraph (D)—
6	"(I) shall not take into account
7	comorbidities; and
8	"(II) shall take into account age
9	for purposes of distinguishing between
10	individuals who are under 18 years of
11	age and those who are 18 years of age
12	and older but shall not include any
13	other adjustment for age for patients
14	18 years of age and older;
15	"(ii) the Secretary shall reassess any
16	adjustments related to patient weight
17	under such clause;
18	"(iii) the payment adjustment de-
19	scribed in clause (ii) of such subparagraph
20	shall not be included; and
21	"(iv) take into account reasonable
22	costs for determining the payment rate
23	consistent with paragraph (2)(B).".
24	(b) Inclusion of Network Fee as an Allow-
25	ABLE COST.—Section 1881(b)(14) of the Social Security

1	Act (42 U.S.C. 1395rr(b)(14)), as amended by subsection
2	(a), is amended by adding at the end the following new
3	subparagraph:
4	"(K) Not later than January 1, 2022, the
5	Secretary shall amend the ESRD facility cost
6	report to include the per treatment network fee
7	(as described in paragraph (7)) as an allowable
8	cost or offset to revenue.".
9	(c) Determination of Productivity Adjust-
10	MENT.—Section 1886(b)(3)(B)(xi) of the Social Security
11	Act (42 U.S.C. 1395ww(b)(3)(B)(xi)) is amended—
12	(1) in subclause (I), by striking "For 2012"
13	and inserting "Subject to subclause (IV), for 2012";
14	and
15	(2) by adding at the end, the following new sub-
16	clause:
17	"(IV) For each of 2022 through
18	2025, the productivity adjustment de-
19	scribed in subclause (II) shall be zero
20	for a payment system in any year in
21	which the Medicare Payment Advisory
22	Commission estimates that payments
23	under this title pursuant to such pay-
24	ment system, on an aggregate na-
25	tional basis, exceed costs, on an ag-

1	gregate national basis, by 3.0 percent
2	or less.".
3	(d) Payment for New and Innovative Drugs
4	AND BIOLOGICALS THAT ARE RENAL DIALYSIS SERV-
5	ICES.—Section 1881(b)(14) of the Social Security Act (42
6	U.S.C. 1395ww(b)(14)), as amended by subsections (a)
7	and (b), is amended by adding the following new subpara-
8	graph—
9	"(L) Payment for New and innovative
10	DRUGS, BIOLOGICALS, AND DEVICES THAT ARE
11	RENAL DIALYSIS SERVICES.—
12	"(i) In general.—For drugs or
13	biologicals determined to be within a func-
14	tional category, the Secretary, in consulta-
15	tion with stakeholders, shall ensure that
16	the single payment amount is adequate to
17	cover the cost of new innovative drugs or
18	biologicals and increase the single payment
19	amount if the Secretary determines such
20	payment amount is not adequate to cover
21	such cost. In carrying out the preceding
22	sentence, the Secretary shall use the cost
23	and utilization data collected during the
24	three-year transitional payment period, as
25	otherwise described in the final regulation

published on November 14, 2018 (83 Fed.
 Reg. 56922 et seq.).

"(ii) Money to follow the patient.—The Secretary, through notice and comment rulemaking, shall implement a policy for any drug or biological that is not provided to the 'average' patient that results in the amount by which the single payment amount is increased pursuant to this subparagraph shall be paid only when a provider or renal dialysis facility has demonstrated that it has administered the drug or biological to a patient.".

14 (e) New Devices and Other Technologies.—As 15 part of the promulgation of the annual rule for the Medicare end-stage renal disease prospective payment system 16 17 under section 1881(b)(14) of the Social Security Act (42) 18 U.S.C. 1395rr(b)(14)) for calendar year 2022, and in con-19 sultation with stakeholders, the Secretary shall ensure 20 that the single payment amount is adequate to cover the 21 cost of the new innovative device or other technology with 22 substantial clinical improvement and increase the single 23 payment amount if the Secretary determines such payment amount is not adequate to cover such cost. In carrying out the preceding sentence, the Secretary shall use

3

4

6

7

8

9

10

11

12

13

1	the cost and utilization data collected during a three-year
2	transitional payment period, as otherwise described in the
3	final regulation published on November 9, 2020 (85 Fed.
4	Reg. 71398 et seq.).
5	TITLE III—INCREASING PATIENT
6	ACCESS TO QUALITY PER-
7	FORMANCE BY IMPROVING
8	THE ACCURACY AND TRANS-
9	PARENCY OF END-STAGE
10	RENAL DISEASE QUALITY
11	PROGRAMS
12	SEC. 301. IMPROVING PATIENT DECISION MAKING AND
13	TRANSPARENCY BY CONSOLIDATING AND
14	MODERNIZING QUALITY PROGRAMS.
15	(a) Measures.—Section 1881(h)(2) of the Social
16	Security Act (42 U.S.C. 1395rr(h)(2)) is amended—
17	(1) by striking subparagraph (A) and inserting
18	the following:
19	"(A) The measures specified under this
20	paragraph with respect to the year involved
21	shall be selected by the Secretary in consulta-
22	tion with stakeholders to promote improvement
23	in beneficiary outcomes and shared decision-
24	making with beneficiaries and their caregivers.
25	When selecting measures specified under this

paragraph, the Secretary shall take into ac-1 2 count clinical gaps in care, underutilization that 3 may lead to beneficiary harm, patient safety, 4 and outcomes."; (2) in subparagraph (B)(i), by striking "sub-5 paragraph (A)(iv)" and inserting "subparagraph 6 (A)";7 8 (3) by striking subparagraph (E); and 9 (4) by adding at the end the following new sub-10 paragraphs: "(E) Weighting Limitation.—No single 11 12 measure specified by the Secretary or individual 13 measure within a composite measure so speci-14 fied may be weighted less than 10 percent of 15 the total performance score. 16 "(F) STATISTICALLY VALID AND RELI-17 ABLE.—In specifying measures under subpara-18 graph (A), the Secretary shall only specify 19 measures that have been shown to be statis-20 tically valid and reliable through testing.". 21 (b) Endorsement.—Section 1881(h)(2)(B) of the 22 Social Security Act (42 U.S.C. 1395rr(h)(2)(B)) is 23 amended— 24 (1) in clause (ii), by adding at the end the following new sentence: "The exception under the pre-25

1	ceding sentence shall not apply to a measure that
2	the entity with a contract under section 1890(a) (or
3	a similar entity) considered but failed to endorse.";
4	and
5	(2) by adding at the end the following new
6	clause:
7	"(iii) Composite measures.—
8	Clauses (i) and (ii) shall apply to com-
9	posite measures in the same manner as
10	such clauses apply to individual meas-
11	ures.".
12	(c) Requirements for Dialysis Facility Com-
13	PARE STAR RATING PROGRAM.—Section 1881(h)(6) of
14	the Social Security Act (42 U.S.C. 1395rr(h)(6)) is
15	amended by adding at the end the following new subpara-
16	graph:
17	"(E) Requirements for any dialysis
18	FACILITY COMPARE STAR RATING PROGRAM.—
19	To the extent that the Secretary maintains a
20	dialysis facility compare star rating program,
21	under such a program the Secretary—
22	"(i) shall assign stars using the same
23	methodology and total performance score
24	results from the quality incentive program
25	under this subsection;

1	"(ii) shall determine the stars using
2	the same methodology used under such
3	quality incentive program; and
4	"(iii) shall not use a forced bell curve
5	when determining the stars or rebaselining
6	the stars.".
7	(d) Incentive Payments.—Section 1881(h)(1) of
8	the Social Security Act (42 U.S.C. 1395rr(h)(1)) is
9	amended by adding at the end the following new subpara-
10	graph:
11	"(D) Incentive payments.—
12	"(i) In general.—In the case of a
13	provider of services or a renal dialysis fa-
14	cility that the Secretary determines exceeds
15	the attainment performance standards
16	under paragraph (4) with respect to a
17	year, the Secretary may make a bonus
18	payment to the provider or facility (pursu-
19	ant to a process established by the Sec-
20	retary).
21	"(ii) Funding.—The total amount of
22	bonus payments under clause (i) in a year
23	shall be equal to the total amount of re-
24	duced payments in a year under subpara-
25	graph (A).

1	"(iii) No effect in subsequent
2	YEARS.—The provisions of subparagraph
3	(C) shall apply to a bonus payment under
4	this subparagraph in the same manner
5	subparagraph (C) applies to a reduction
6	under such subparagraph.".
7	(e) Effective Date.—The amendments made by
8	this section shall apply to items and services furnished on
9	or after January 1, 2022.
10	TITLE IV—EMPOWERING
11	PATIENTS
12	SEC. 401. MEDIGAP COVERAGE FOR BENEFICIARIES WITH
13	END-STAGE RENAL DISEASE.
13 14	END-STAGE RENAL DISEASE. (a) GUARANTEED AVAILABILITY OF MEDIGAP POLI-
14	(a) Guaranteed Availability of Medigap Poli-
14 15	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.—
14 15 16	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In general.—Section 1882(s) of the So-
14 15 16 17	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In General.—Section 1882(s) of the Social Security Act (42 U.S.C. 1395ss(s)) is amend-
14 15 16 17	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In General.—Section 1882(s) of the Social Security Act (42 U.S.C. 1395ss(s)) is amended—
114 115 116 117 118	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In General.—Section 1882(s) of the Social Security Act (42 U.S.C. 1395ss(s)) is amended— (A) in paragraph (2)—
14 15 16 17 18 19 20	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In General.—Section 1882(s) of the Social Security Act (42 U.S.C. 1395ss(s)) is amended— (A) in paragraph (2)— (i) in subparagraph (A), by striking
114 115 116 117 118 119 220 221	(a) Guaranteed Availability of Medigap Policies to All ESRD Medicare Beneficiaries.— (1) In General.—Section 1882(s) of the Social Security Act (42 U.S.C. 1395ss(s)) is amended— (A) in paragraph (2)— (i) in subparagraph (A), by striking "is 65" and all that follows through the

1	"(ii) entitled to benefits under 226A(b) and is
2	enrolled for benefits under part B."; and
3	(ii) in subparagraph (D), in the mat-
4	ter preceding clause (i), by inserting "(or
5	is entitled to benefits under 226A(b))"
6	after "is 65 years of age or older"; and
7	(B) in paragraph (3)(B)—
8	(i) in clause (ii), by inserting "(or is
9	entitled to benefits under 226A(b))" after
10	"is 65 years of age or older"; and
11	(ii) in clause (vi), by inserting "(or
12	under 226A(b))" after "at age 65".
13	(2) Effective date.—The amendments made
14	by paragraph (1) shall apply to Medicare supple-
15	mental policies effective on or after January 1,
16	2022.
17	(b) Additional Enrollment Period for Cer-
18	TAIN INDIVIDUALS.—
19	(1) One-time enrollment period.—
20	(A) In general.—In the case of an indi-
21	vidual described in subparagraph (B), the Sec-
22	retary of Health and Human Services shall es-
23	tablish a one-time enrollment period during
24	which such an individual may enroll in any
25	Medicare supplemental policy under section

1	1882 of the Social Security Act (42 U.S.C.
2	1395ss) of the individual's choosing.
3	(B) Enrollment period.—The enroll-
4	ment period established under subparagraph
5	(A) shall begin on January 1, 2023, and shall
6	end June 30, 2023.
7	(2) Individual described.—An individual de-
8	scribed in this paragraph is an individual who—
9	(A) is entitled to hospital insurance bene-
10	fits under part A of title XVIII of the Social
11	Security Act under section 226A(b) of such Act
12	(42 U.S.C. 426–1);
13	(B) is enrolled for benefits under part B of
14	such title XVIII; and
15	(C) would not, but for the provisions of,
16	and amendments made by, subsection (a) be eli-
17	gible for the guaranteed issue of a Medicare
18	supplemental policy under paragraph (2) or (3)
19	of section 1882(s) of such Act (42 U.S.C.
20	1395ss(s)).
21	SEC. 402. NETWORK ADEQUACY STANDARDS FOR DIALYSIS
22	SERVICES.
23	Section 1852(d) of the Social Security Act (42 U.S.C.
24	1395w-22(d)) is amended by adding at the end the fol-
25	lowing new paragraph:

1	"(7) Network adequacy requirements for	
2	DIALYSIS SERVICES.—For plan year 2022 and sub-	
3	sequent plan years, the Secretary shall apply the	
4	network adequacy standards under this subsection	
5	with respect to access to dialysis services—	
6	"(A) using the time and distance stand-	
7	ards in effect for plan year 2020; and	
8	"(B) without regard to the final rule titled	
9	'Medicare Program; Contract Year 2021 Policy	
10	and Technical Changes to the Medicare Advan-	
11	tage Program, Medicare Prescription Drug	
12	Benefit Program, and Medicare Cost Plan Pro-	
13	gram' (85 Fed. Reg. 33796).".	
14	SEC. 403. ALLOWING INDIVIDUALS WITH KIDNEY FAILURE	
15	TO RETAIN ACCESS TO PRIVATE INSURANCE.	
16	(a) In General.—Section 1862(b)(1)(C) of the So-	
17	cial Security Act (42 U.S.C. 1395y(b)(1)(C)) is amend-	
18	ed—	
19	(1) in the last sentence, by inserting "and be-	
20	fore January 1, 2022" after "prior to such date";	
21	and	
22	(2) by adding at the end the following new sen-	
23	tence: "Effective for items and services furnished on	
24	or after January 1, 2022 (with respect to periods	

- prior to such date), clauses (i) and (ii) shall be ap-
- 2 plied by substituting '42-month' for '12-month' each
- 3 place it appears.".
- 4 (b) Effective Date.—The amendments made by
- 5 this subsection shall take effect on the date of enactment
- 6 of this Act. For purposes of determining an individual's
- 7 status under section 1862(b)(1)(C) of the Social Security
- 8 Act (42 U.S.C. 1395y(b)(1)(C)), as amended by sub-
- 9 section (a), an individual who is within the coordinating
- 10 period as of the date of enactment of this Act shall have
- 11 that period extended to the full 42 months described in
- 12 the last sentence of such section, as added by the amend-
- 13 ment made by subsection (a)(2).

 \bigcirc